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Abstract
Background: It is unclear whether appropriate empiric antimicrobial therapy improves outcomes in patients with
bacteremia due to Escherichia coli or Klebsiella. The objective of this study is to assess the impact of appropriate empiric
antimicrobial therapy on in-hospital mortality and post-infection length of stay in patients with Escherichia coli or Klebsiella
bacteremia while adjusting for important confounding variables.
Methods: We performed a retrospective cohort study of adult patients with a positive blood culture for E. coli or
Klebsiella between January 1, 2001 and June 8, 2005 and compared in-hospital mortality and post-infection length of stay
between subjects who received appropriate and inappropriate empiric antimicrobial therapy. Empiric therapy was
defined as the receipt of an antimicrobial agent between 8 hours before and 24 hours after the index blood culture was
drawn and was considered appropriate if it included antimicrobials to which the specific isolate displayed in vitro
susceptibility. Data were collected electronically and through chart review. Survival analysis was used to statistically
assess the association between empiric antimicrobial therapy and outcome (mortality or length of stay). Multivariable
Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI).
Results: Among 416 episodes of bacteremia, 305 (73.3%) patients received appropriate empiric antimicrobial therapy.
Seventy-one (17%) patients died before discharge from the hospital. The receipt of appropriate antimicrobial agents was
more common in hospital survivors than in those who died (p = 0.04). After controlling for confounding variables, there
was no association between the receipt of appropriate empiric antimicrobial therapy and in-hospital mortality (HR, 1.03;
95% CI, 0.60 to 1.78). The median post-infection length of stay was 7 days. The receipt of appropriate antimicrobial
agents was not associated with shortened post-infection length of stay, even after controlling for confounding (HR, 1.11;
95% CI 0.86 to 1.44).
Conclusion: Appropriate empiric antimicrobial therapy for E. coli and Klebsiella bacteremia is not associated with lower
in-hospital mortality or shortened post-infection length of stay. This suggests that the choice of empiric antimicrobial
agents may not improve outcomes and also provides data to support a randomized trial to test the hypothesis that use
(and overuse) of broad-spectrum antibiotics prior to the availability of culture results is not warranted.
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Background
Escherichia coli and Klebsiella pneumoniae are the leading
causes of Gram-negative bloodstream infections in the
U.S. and Canada[1]. The overall mortality associated with
E. coli bacteremia may be as high as 20% [2-4], while the
mortality for K. pneumoniae bacteremia has been esti-
mated to range from 19–50%[2,4-6]. In addition, Gram-
negative bacilli are becoming increasingly resistant to
antimicrobials. The National Nosocomial Infections Sur-
veillance (NNIS) System reported a 47% increase in noso-
comial infections due to third-generation cephalosporin-
resistant K. pneumoniae in 2003 compared to the previous
five years[7]. Increasing antimicrobial resistance of these
organisms may decrease the likelihood of receiving appro-
priate empiric antimicrobial therapy.
Pathogen-directed, "appropriate" antimicrobial therapy is
considered fundamental in the treatment of bacteremia.
Early in the course of infection, however, the causative
organism is typically unknown and the choice of therapy
is empiric, thus clinicians often choose broad-spectrum
antimicrobials to cover a wide range of potential patho-
gens. This strategy may result in increases in cost, adverse
events and antimicrobial resistance and therefore, it is
important to determine if there is a true association with
patient outcome. Research to date, however, has not con-
sistently demonstrated an association between receipt of
appropriate empiric antimicrobial therapy and improved
outcomes in patients with bacteremia due to E. coli or
Klebsiella species [8-19].
Most studies which have evaluated the effect of empiric
antimicrobial therapy on patient outcomes included bac-
teremia due to all bloodstream pathogens or to Gram-
negative organisms in general, thus decreasing their statis-
tical power to evaluate outcomes specific to E. coli or Kleb-
siella  bacteremias. To our knowledge, five studies have
exclusively examined the association between empiric
antimicrobial therapy and outcome among patients with
E. coli or Klebsiella bacteremia[8,9,15,18,19]. These studies
were limited in their generalizability either by small sam-
ples or by including only episodes of bacteremia due to
extended-spectrum beta-lactamase producing
strains[8,9,15]. In addition, while most studies controlled
for severity of illness by using some aggregate score, at
least two of these studies controlled for severity of illness
after the onset of bacteremia[18,19] while two other stud-
ies did not clearly state when this variable was meas-
ured[9,15]. We argue that measurement of severity of
illness at the time of bacteremia or later may reflect com-
plications of the current infection and not the patient's
underlying disease status. Therefore, aggregate scores used
to approximate severity of illness should be measured at
some time point prior to the onset of bacteremia. In this
study, we aimed to evaluate the effect of empiric therapy
on in-hospital mortality and post-infection length of stay
among adult patients with bacteremia due to E. coli or
Klebsiella species, while controlling for severity of illness
before the detection of bacteremia.
Methods
Study Population
This study was performed at the University of Maryland
Medical Center (UMMC), a 656-bed tertiary-care hospital
located in Baltimore, Maryland. The UMMC provides spe-
cialized medical and surgical care, including bone marrow
and solid organ transplantation. All adult patients (> 18
years of age) with a positive blood culture for either E. coli
or Klebsiella species between January 1, 2001 and June 8,
2005 were eligible for inclusion. Patients were identified
using the UMMC central data repository, a relational data-
base that contains patient clinical and administrative
data. Patients with multiple episodes of bacteremia dur-
ing the study period were allowed to enter the cohort mul-
tiple times only if the episodes of bacteremia occurred
during separate hospital admissions. Patients with a pol-
ymicrobial bacteremia were included in this study. How-
ever, cases in which the index blood culture was positive
for both E. coli and Klebsiella species were only included
once.
Study Design
We used a retrospective cohort design to evaluate the
effects of empiric antimicrobial therapy on morbidity and
mortality associated with E. coli and Klebsiella bacteremia.
The primary outcome measure, in-hospital mortality, was
compared among subjects who received appropriate and
inappropriate empiric therapy. We assessed post-infection
length of stay (the time period from the date the index
blood culture was obtained to the date of discharge) as the
secondary outcome measure. This study was approved by
the University of Maryland Institutional Review Board
and was deemed exempt from informed consent.
Variable definitions
Empiric antimicrobial therapy was defined as the receipt
of an antimicrobial agent by the patient between 8 hours
before and 24 hours after the index blood culture was
drawn. We chose this early time period in attempt to
exclude scenarios where preliminary microbiologic data
were available (e.g. knowledge of whether the organism
was a lactose-fermenter) since this may have influenced
antimicrobial choice. Empiric therapy was considered
appropriate if it included intravenous and/or oral antimi-
crobials to which the specific isolate (or isolates, if pol-
ymicrobial) displayed in vitro susceptibility.
Severity of illness prior to bacteremia was assessed by cal-
culating a modified Acute Physiology Score (APS) based
on the Acute Physiology and Chronic Health EvaluationBMC Infectious Diseases 2008, 8:116 http://www.biomedcentral.com/1471-2334/8/116
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(APACHE) III score 24 hours before the time the index
culture was obtained [20-22]. We chose this time point to
better ensure that the aggregate score accurately reflected
the baseline severity of illness of each patient and did not
include values that occurred as a consequence of the bac-
teremia [23]. If the index blood culture was obtained
within 24 hours of hospital admission then the modified
APS was calculated at admission. The APACHE III score
was designed for use among intensive care unit (ICU)
patients. Since this study included participants who many
not have been in an ICU at the time of bacteremia, we
modified the score by excluding variables that were not
applicable to our study population (i.e. pulmonary arte-
rial gradient, urine output, neurologic status and ventila-
tor data) as has been done in other studies [20-22,24].
The presence of pre-existing comorbid conditions was
determined using the Chronic Disease Score (CDS), an
aggregate comorbidity measure which utilizes patient
medications as indicators for the presence of comorbid
conditions[25]. In this study, as has been done in other
studies, the CDS was calculated based upon the medica-
tions ordered within the first 24 hours of hospital admis-
sion [20,26,27].
Data Collection
The central data repository was used to collect administra-
tive, pharmacy, laboratory and outcome data for all
patients. The data contained within the tables of the
repository have been validated against medical records for
this and previous research studies and have positive and
negative predictive values of greater than 98%[20,27].
Variables electronically collected included demographics,
date and time the blood culture of interest was obtained,
time at risk (i.e. time from hospital admission to collec-
tion of index blood culture), post-infection length of stay,
time to susceptibility results (i.e. time from collection of
index blood culture to receipt of antimicrobial suscepti-
bility testing results), antimicrobial susceptibility results
for the organism, laboratory data included in the APACHE
III score and medication data used to calculate the CDS.
For polymicrobial bacteremias, all co-infecting species
were identified and the antimicrobial susceptibility pro-
file was reviewed for all organisms.
Patient medical records were used to collect additional
information such as vital signs and the presence of a cen-
tral venous catheter at time of culture collection. Medica-
tion administration records were examined for each
patient to determine if and when the patient received
empiric antimicrobial therapy.
Statistical analysis
All data were analyzed using SAS software version 9.1
(SAS Institute, Cary, NC). The Fisher's exact test and Chi-
square test were used to compare categorical variables and
the Student's t-test was used for continuous variables.
Data for both outcomes were analyzed and compared
between the two groups (appropriate and inappropriate
empiric therapy) using Kaplan-Meier survival models. The
log-rank and Wilcoxon tests were used to compare sur-
vival curves. Multivariable survival analysis, using the Cox
proportional hazards model, was done to assess the asso-
ciation between empiric antimicrobial therapy and the
outcomes, in-hospital mortality and length of stay, while
adjusting for potential confounding factors. Variables that
were significantly associated (p < 0.05) with the outcome
or that modified the regression model coefficient for
empiric therapy by more than 10% were included in the
final multivariable model. The exposure, appropriate
therapy, was forced into the model regardless of statistical
significance. For the outcome of length of stay, the event
was discharge from hospital and therefore, the term sur-
vival refers to patients remaining in the hospital (i.e.,
those who "survived" from being discharged). Patients
who died in the hospital were excluded from this analysis
because their hospital stay was shortened by death. All
tests of significance were two-tailed, and p-values of less
than 0.05 were considered significant. Hazards ratios
(HRs) and 95% confidence intervals (CIs) were calcu-
lated. We examined the associations between appropriate
empiric therapy and outcomes for all observations, and
then again after stratification by organism.
Results
During the study period, 416 episodes of E. coli and Kleb-
siella  bacteremia were included. Two-hundred and
twenty-five (54.0%) bacteremias were due to E. coli and
203 (48.8%) were due to Klebsiella species (175 K. pneu-
moniae, 28 K. oxytoca, 2 non-speciated Klebsiella isolates).
Two hundred and three (48.8%) of the positive cultures
were obtained at or after 48 hours following admission
(i.e. hospital-acquired) and the remaining 213 (51.2%)
were obtained within the first 48 hours of admission (i.e.
community-acquired). Eighty-nine (21.4%) of the bacter-
emia episodes were polymicrobial and 11 of these
included both E. coli and K. pneumoniae. The characteris-
tics of this cohort are presented in Table 1.
Three-hundred and five (73.3%) patients received appro-
priate empiric antimicrobials according to our study defi-
nition. For the antimicrobial sensitivity patterns of the
isolates please see Additional File 1: Antimicrobial Sus-
ceptibilities of Escherichia coli and Klebsiella Bloodstream
Isolates. The median time (interquartile range, IQR)
between culture collection and receipt of antimicrobial
susceptibility testing results was 3.1 days (2.6 to 3.9 days).BMC Infectious Diseases 2008, 8:116 http://www.biomedcentral.com/1471-2334/8/116
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The mean modified APS 24 hours before culture collec-
tion was 22.7 (SD = 14.2). For 199 (48%) episodes of bac-
teremia, the index blood culture was drawn within 24
hours of hospital admission and therefore the compo-
nents used to calculate the APS values used were measured
at the time of hospital admission.
In-hospital mortality
Seventy-one (17.0%) patients died before discharge from
the hospital. In-hospital mortality among patients with E.
coli bacteremia was 17.8% (40/225) and among patients
with Klebsiella bacteremia was 18.2% (37/203). Table 2
displays characteristics of hospital survivors and non-sur-
vivors. Factors significantly associated with in-hospital
mortality included: older age, polymicrobial bacteremia,
presence of a central venous catheter at the time of culture,
higher baseline severity of illness and shorter time at risk.
In addition, the receipt of empiric appropriate antimicro-
bial therapy was more common among hospital survivors
than those who died (p = 0.04).







Age (mean in years, SD) 55.3 ± 16.2 55.7 ± 16.2 54.9 ± 15.8
Male sex 45.3% (188/415) 49.1% (110/224) 40.9% (83/203)
Hospital-acquired Bacteremia† 48.8% (203/416) 39.1% (88/225) 59.6% (121/203)
Polymicrobial bacteremia 21.4% (89/416) 20.9% (47/225) 26.6% (54/203)
Appropriate empiric antimicrobial therapy 73.3% (305/416) 74.7% (168/225) 70.9% (144/203)
Admission to the ICU 37% (154/416) 36.0% (81/225) 39.4% (80/203)
Mechanical ventilation at admission 9.6% (40/415) 6.7% (15/224) 13.3% (27/230)
Mechanical ventilation at culture 16.6% (69/415) 14.7% (33/224) 19.7% (40/203)
Presence of central line at culture 54.4% (225/414) 43.5% (97/223) 68.5% (139/203)
APS before culture (mean, SD) 22.7 ± 14.2 22.5 ± 14.6 22.9 ± 13.7
Chronic disease score (mean, SD) 7.1 ± 3.9 6.9 ± 4.0 7.4 ± 3.7
Time at risk (median in days, IQR)†† 1.5 (0.1 to 10.0) 0.4 (0.1 to 6.9) 5.1 (0.2 to 13.3)
Time to susceptibility (median in days, IQR)††† 3.1 (2.6 to 3.9) 3.1 (2.6 to 3.9) 3.2 (2.6 to 4.1)
Length of stay (median in days, IQR)†††† 7.0 (3.9 to 14.2) 6.2 (3.7 to 12.1) 8.7 (4.3 to 17.6)
In-hospital mortality 17.0% (71/416) 17.8% (40/225) 18.2% (37/203)
ICU – Intensive care unit
SD – standard deviation
APS – modified acute physiology score
IQR – interquartile range
* Eleven patients had polymicrobial bacteremia which included both E. coli and Klebsiella species
†Bacteremia which occurred at or greater than 48 hours after hospital admission
††Time at risk is the time from hospital admission to index culture collection
†††Time to susceptibility is the time from index culture collection to the receipt of antibiotic susceptibility testing results
††††Length of stay is the time from index culture collection to hospital discharge or death
Table 2: Predictors for hospital mortality in patients with bacteremia due to E. coli or Klebsiella
Variable Hospital Non-survivors
n = 71 (17%)
Hospital Survivors
n = 345 (83%)
P-value
Age (mean in years, SD) 59.6 ± 14.6 54.4 ± 16.3 0.01
Male sex (n, %) 29(40.9) 159(46.2) 0.41
Polymicrobial bacteremia (n, %) 22(31.0) 67(19.4) 0.03
Appropriate empiric antimicrobial therapy (n, %) 45(63.4) 260(75.4) 0.04
Presence of central line at time of culture (n, %) 48(67.6) 177 (51.6) 0.01
APS before culture (mean, SD) 34.9 ± 14.8 20.2 ± 13.8 < 0.01
Chronic disease score (mean, SD) 7.9 ± 3.9 7.0 ± 3.9 0.08
Time at risk (median in days, IQR)† 8.0 (0.17 to 21.4) 0.9 (0.1 to 8.8) < 0.01
Time to susceptibility (median in days, IQR)†† 3.2 (2.8 to 4.1) 3.0 (2.6 to 3.9) 0.02
APS – modified acute physiology score
IQR – interquartile range
†Time at risk is the time from hospital admission to index culture collection
††Time to susceptibility is the time from index culture collection to the receipt of antibiotic susceptibility testing results
P-values were calculated using the Fisher's exact test or Chi-squared tests for categorical variables and the Student's t-test for continuous variables.BMC Infectious Diseases 2008, 8:116 http://www.biomedcentral.com/1471-2334/8/116
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After controlling for confounding variables (age, severity
of illness, the presence of a central venous catheter at the
time of culture), there was no association between the
receipt of appropriate empiric antimicrobial therapy and
mortality (HR, 1.03; 95% CI, 0.60 to 1.78)(Table 3). Fig-
ure 1 shows the survival curves for patients with bactere-
mia who received appropriate and inappropriate empiric
antimicrobial therapy based on the Cox proportional haz-
ards models. Multivariable survival analysis suggested
that severity of illness (HR, 1.06; 95%CI, 1.05 to 1.08)
and age (HR, 1.02; 95% CI, 1.01 to 1.04) were independ-
ent predictors of in-hospital mortality. Similar analyses
were performed separately for E. coli and Klebsiella bacter-
emia (Table 3).
Length of stay
The median post-infection length of stay in the hospital
after collection of the index blood culture was 7 days
(IQR, 3.9 to 14.2 days). The median post-infection length
of stay among patients with E. coli bacteremia was 6.2
days (IQR, 3.7 to 12.1 days) and among patients with
Klebsiella bacteremia was 8.7 days (IQR, 4.3 to 17.6 days).
In bivariable analyses, male sex (p = 0.04), presence of a
central venous catheter at the time of culture (p < 0.01),
severity of illness (p < 0.01), CDS (p < 0.01), and time at
risk (p < 0.01) were statistically associated with an
increased post-infection length of stay. However, the
receipt of appropriate antimicrobial agents within 24
hours of the time the index blood culture was obtained
was not associated with post-infection length of stay (p =
0.24).
After controlling for confounding variables (the presence
of a central venous catheter at the time of culture, severity
of illness and time at risk), appropriate empiric antimicro-
bial therapy was not associated with time to discharge
from the hospital (HR, 1.11; 95% CI, 0.86 to 1.44, Table
3). Figure 2 shows the time to discharge curves for patients
who received appropriate and inappropriate empiric anti-
microbial therapy based on the Cox proportional hazard
models. For this curve the "event" is hospital discharge
and the term "survival" refers to patients who remain in
the hospital. Multivariable survival analysis demonstrated
that severity of illness (HR, 0.99; 95% CI, 0.97 to 0.99),
the presence of a central venous catheter at the time of cul-
ture (HR, 0.67; 95% CI, 0.54 to 0.85) and the time at risk
(HR, 0.66; 95% CI, 0.52 to 0.83) were independent pre-
dictors of time to discharge (i.e. were associated with an
increased length of stay).
Discussion
We evaluated the effect of empiric antimicrobial therapy
on outcomes among a cohort of patients with E. coli and
Klebsiella  bacteremia and did not observe a significant
association between appropriate empiric antimicrobial
therapy and in-hospital mortality or post-infection length
of stay, after controlling for important confounders such
as severity of illness.
Though it may seem logical that the use of appropriate
antimicrobials early in the course of therapy for E. coli or
Klebsiella bacteremia would lead to improved outcomes;
this association has not been clearly established. Differ-
ences in methodologies among previous studies may
explain why some, but not all studies have observed sig-
nificant associations between appropriate therapy and
clinical outcomes. Previously published studies have var-
ied by infecting organism, patient population, classifica-
tion of appropriate therapy and the time this variable was
measured, whether or not severity of illness was control-
led for in the final analysis, and the time at which severity
of illness was measured.
Empiric therapy is considered to be the receipt of antimi-
crobials during the time period prior to the availability of
bacterial culture and susceptibility testing results. The
empiric therapy time intervals vary in the literature, from
within 24 hours of the bacterial culture results to the time
antimicrobial susceptibility testing results are availa-
ble[28]. In some instances, however, preliminary results
may be available to physicians prior to definitive suscep-
tibility results which could influence antibiotic choice and
thus bias the analyses from finding a beneficial effect of
appropriate empiric therapy. For this reason, we chose to
In-Hospital Survival Curve based on Cox Proportional Haz- ards Models Figure 1
In-Hospital Survival Curve based on Cox Propor-
tional Hazards Models. In-hospital survival among patients 
who received appropriate (grey line) and inappropriate 
empiric therapy (black line).BMC Infectious Diseases 2008, 8:116 http://www.biomedcentral.com/1471-2334/8/116
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evaluate empiric therapy early in the course of the disease
process, from 8 hours prior to the time in which the index
culture was obtained to 24 hours afterwards.
Underlying severity of illness is an important predictor of
mortality. Therefore, physicians may be more likely to
prescribe broad-spectrum empiric antimicrobial therapy
for presumed bacteremia in patients who have more
severe illness at baseline[16]. Due to the established asso-
ciation with mortality and the putative association with
antimicrobial therapy, baseline severity of illness is a
potential confounding factor of the association between
these two variables. As a result, baseline severity of illness
should be controlled for in any analysis comparing anti-
microbial therapy and outcomes in patients with bactere-
mia. Several studies have measured severity of illness at
the time of bacteremia or later. However, some compo-
nents of the APS measured in this time period are likely to
be affected by the infection and may not reflect the base-
line severity of illness and thus should not be controlled
for[23]. The optimal time to measure severity of illness is
just prior to the onset of bacteremia, but this time period
is difficult to identify. In this study we measured the sever-
ity of illness using the modified APS 24 hours before the
index culture was obtained. Yet, for some observations the
index blood culture was obtained within 24 hours of
admission to the hospital and in these instances the mod-
ified APS was calculated using variables collected at the
time of admission. In order to evaluate the impact of dif-
ferent measurement times, we performed a secondary
analysis on the 217 observations for which the modified
APS was calculated at or greater than 24 hours prior to the
time the index blood culture was obtained and obtained
results similar to those presented for the entire cohort
(data not shown).
A limitation of this study is that the design is observa-
tional, and therefore it is impossible to completely control
for all variables which may be associated with both mor-
tality and the receipt of empiric antibiotics. Also, because
this study was retrospective and observational, antimicro-
bial choice was made solely by physicians (there are no
specific hospital-based protocols for the use of antimicro-
bial agents at this institution). We were unable to collect
data on other potential factors which may have influenced
the physician's choice of empiric therapy, such as individ-
ual prescribing patterns and physician knowledge of a
patient's previous infections, previous antimicrobial sus-
Table 3: Multivariable Cox Proportional Hazards Models
Outcome = In-hospital Mortality Outcome = Length of Stay
Variable Hazard Ratio (95% CI) Hazard Ratio (95% CI)
All Bacteremias (N = 416)
Appropriate Antibiotics -8 to 24 hours 1.03 (0.60 to 1.78) 1.11 (0.86 to 1.44)
Age (per year) 1.02 (1.01 to 1.04) NS
Male Sex -- NS
Central line at time of culture -- 0.67 (0.54 to 0.85)
Time at risk† (per day) NS 0.66 (0.52 to 0.83)
APS 24 hours before culture 1.06 (1.05 to 1.08) 0.99 (0.97 to 0.99)
Polymicrobial bacteremia NS --
E. coli Bacteremia (N = 225)
Appropriate Antibiotics -8 to 24 hours 1.11 (0.52 to 2.34) 1.04 (0.72 to 1.51)
Central line at time of culture NS NS
Time at risk† NS 0.66 (0.47 to 0.91)
APS 24 hours before culture 1.06 (1.04 to 1.08) 0.98 (0.97 to 1.00)
Polymicrobial bacteremia NS --
Klebsiella Bacteremia (N = 203)
Appropriate Antibiotics -8 to 24 hours 0.84 (0.42 to 1.70) 1.21 (0.84 to 1.73)
Age 1.03 (1.01 to 1.06) --
Time at risk† -- 0.65 (0.47 to 0.90)
Central line at time of culture -- 0.62 (0.44 to 0.86)
APS 24 hours before culture 1.06 (1.03 to 1.09) 0.98 (0.97 to 1.00)
APS – modified acute physiology score
NS – not significant (p > 0.05)
-- Not included in final model
†Time at risk is the time from hospital admission to index culture collection
NB: Hazard Ratios are reported per one unit increase in the study variable; for example a HR of 1.06 for APS can be interpreted as a 6% increase 
in the hazard of death for each one unit increase in APS; therefore for an increase in APS of 5 points the hazard of death would increase by 30%.BMC Infectious Diseases 2008, 8:116 http://www.biomedcentral.com/1471-2334/8/116
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ceptibility data or prior antibiotic use. Additionally, dos-
ing of antimicrobial agents was not considered and
therefore it is possible that selection of appropriate anti-
microbials may lead to clinical failure if the antimicrobial
agent was not adequately dosed. Furthermore, due to fre-
quent changes in antimicrobial agents and inadequate
power we were unable to consider the specific antimicro-
bial agent received in the analysis. Another potential lim-
itation in this study is the use of a modified APS score to
measure severity of illness in non-critically ill patients.
While this score has not been validated specifically for this
purpose, it has been used extensively in the infectious dis-
ease literature[5,9,20,29]. In addition, we did not have
data on patients after discharge from the hospital and
therefore we were limited to evaluating in-hospital moral-
ity as our outcome instead of overall mortality. Finally, we
did not evaluate the source of bacteremia, nor source con-
trol such as drainage of abscesses or removal of catheters,
which may be associated with outcomes such as mortality
and length of stay as well as the receipt of antimicrobial
therapy[17].
Conclusion
In conclusion, we observed that appropriate empiric anti-
microbial therapy was not associated with lower in-hospi-
tal mortality or shorter post-infection length of stay after
controlling for important confounding variables. These
data suggest that empiric antimicrobial therapy may not
be critical to patient outcomes among patients with E. coli
or Klebsiella bloodstream infections. One hypothesis to
explain these findings is that definitive therapy (i.e. ther-
apy given after culture results are known) may be a more
important predictor of outcomes following bacteremia
than empiric therapy. Another hypothesis is that the inter-
action between the organism and the particular host is
more critical to the outcome than the specific infection. In
other words, the baseline severity of illness or the presence
of comorbid disease may be more important than the
actual infection and thus after controlling for these con-
founders, no effect is seen. While physicians have been
willing to accept potential increases in antimicrobial
resistance and adverse events in order to prescribe broad-
spectrum empiric therapy with the hope that it will
improve outcomes, this and other studies, suggest that the
use of broad-spectrum empiric therapy may not lead to
improved outcomes. If the benefit of broad-spectrum
therapy is minimal, then a shift to narrower-spectrum
therapy may provide a greater benefit to treated popula-
tions through reduced emergence of resistance and
decreased adverse events. In addition, this study along
with other previously published studies[8,9,15-17] pro-
vide enough equipoise to justify conducting a clinical trial
to determine the actual benefit of empiric broad-spectrum
antimicrobial therapy in patients with suspected Gram-
negative bacteremia.
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